Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Sun BioPharma, Inc. (OTC: SNBP).

Full DD Report for SNBP

You must become a subscriber to view this report.


Recent News from (OTC: SNBP)

Sun BioPharma Provides Business Update and Files Report for Q1 2018
Enrollment of the First Patient in the Front-Line Combination Study of SBP-101 with Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer Expected in May 2018 Data from the Company’s Phase 1 Safety Trial of SBP-101 Accepted for Online Publication in the ...
Source: GlobeNewswire
Date: May, 14 2018 08:00
Sun BioPharma, Inc. Announces Appointment of Susan Horvath as Vice President of Finance and Chief Financial Officer
MINNEAPOLIS, April 16, 2018 (GLOBE NEWSWIRE) -- Sun BioPharma, Inc. (OTCQB: SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of pancreatic diseases, today announced the appointment of Susan Horvath as Vice President of Finance and Chief ...
Source: GlobeNewswire
Date: April, 16 2018 07:49
Sun BioPharma Provides Business Update and Files Annual Report for 2017
Front-Line Combination Study with Gemcitabine and Nab-Paclitaxel to begin patient enrollment early in 2 nd Quarter Raised $1.3M in private financing MINNEAPOLIS, March 21, 2018 (GLOBE NEWSWIRE) -- Sun BioPharma, Inc. (OTCQB:SNBP), a clinical stage biopharmaceutical company develo...
Source: GlobeNewswire
Date: March, 21 2018 08:01
Sun Biopharma, Inc. Files United States Patent Protecting the Manufacturing Process for Its Lead Drug Candidate, SBP-101
MINNEAPOLIS, MN, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Sun BioPharma, Inc. (OTCQB:SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of pancreatic diseases, today announced the acceptance by the U.S. Patent and Trademark Office of a provisiona...
Source: GlobeNewswire
Date: February, 27 2018 09:00
Sun Biopharma, Inc. Announces Initiation of First-Line Combination Study of Sbp-101 With Gemcitabine and Nab-Paclitaxel in Patients With Pancreatic Cancer
MINNEAPOLIS, Jan. 29, 2018 (GLOBE NEWSWIRE) -- – Sun BioPharma, Inc. (OTCQB:SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of pancreatic diseases, today announced its initiation of a first-line dose-escalation study of SBP-...
Source: GlobeNewswire
Date: January, 29 2018 08:48
Sun BioPharma Announces Execution of Reverse Stock Split
MINNEAPOLIS, Minn., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Sun BioPharma, Inc. (OTCQB:SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of pancreatic diseases, announced today that it will implement the previously announced 1-for-10 reverse st...
Source: GlobeNewswire
Date: November, 07 2017 19:21
3 Things In Biotech You Should Learn Today: October 6, 2017
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Janssen drops study of one ischemic stroke indication Company: Janssen, the pharma R&...
Source: SeekingAlpha
Date: October, 06 2017 08:00
Sun BioPharma Achieves Significant Milestone with Successful Completion of Patient Enrollment in Phase 1a Dose Escalation Safety Study of SBP-101 for Patients with Pancreatic Cancer
Updated Preliminary Top-Line Data Continue to Show Signals of Efficacy                      MINNEAPOLIS, Oct. 04, 2017 (GLOBE NEWSWIRE) -- Sun BioPharma, Inc. (OTCQB:SNBP), a clinical stage biopharmaceutical company developing di...
Source: GlobeNewswire
Date: October, 04 2017 08:45
Sun BioPharma Achieves Significant Milestone with Successful Completion of Patient Enrollment in Phase 1a Dose Escalation Safety Study of SBP-101 for Patients with Pancreatic Cancer
Sun BioPharma Achieves Significant Milestone with Successful Completion of Patient Enrollment in Phase 1a Dose Escalation Safety Study of SBP-101 for Patients with Pancreatic Cancer
Source: OTC Markets
Date: October, 04 2017 00:00
Daily OTC Markets Round-Up - 9/18/2017
This article is part of an ongoing series which provides information relevant to stocks on the OTC markets on a daily basis. It provides stocks with the most daily volume, and the biggest winners/losers in terms of changes in stock price. It then provides information on the stocks which have e...
Source: SeekingAlpha
Date: September, 19 2017 14:16

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-20N/A3.95N/AN/A0
2018-08-17N/A3.95N/AN/A0
2018-08-16N/A3.95N/AN/A0
2018-08-15N/A3.95N/AN/A0
2018-08-14N/A3.95N/AN/A0

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-139001,07084.1121Short
2018-08-075001,10045.4545Short
2018-07-091001,1009.0909Cover
2018-06-227717743.5028Short
2018-06-061,9814,50044.0222Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on SNBP.


About Sun BioPharma, Inc. (OTC: SNBP)

Logo for Sun BioPharma, Inc. (OTC: SNBP)

Sun BioPharma Inc. is a clinical stage bio pharmaceutical company developing disruptive therapeutics for significant unmet medical needs. The Company s initial programs are aimed at diseases of the pancreas, including pancreatic cancer and pancreatitis. The Company has completed enrollment in its first in human Phase a clinical safety trial of SBP , in the treatment of previously treated pancreatic cancer patients. The trial established a safe and well tolerated dose. The Company anticipates initiation of patient enrollment in its next clinical trial in the first quarter of which will be a Phase a/ b study of the safety and efficacy of SBP administered in combination with gemcitabine and nab paclitaxel. Sun BioPharma has scientific collaborations with pancreatic disease experts the Mayo Clinic Scottsdale and Cedars Sinai Medical Center in the US, the University of Miami, the Austin Health Cancer Trials Centre and the Ashford Cancer Centre in Australia. SBP is a novel small molecule synthetic polyamine compound designed to exert therapeutic effects in a mechanism of action specific to the pancreas. SBP has been shown to be highly effective in several human pancreatic cancer models, demonstrating superior activity to existing chemotherapy agents. Combination potential has also been shown for pancreatic cancer. SBP is expected to hold an edge over current pancreatic cancer therapies, as it specifically targets the exocrine pancreas.

 

Contact Information

 

 

Current Management

  • Michael T. Cullen / CoFounder
  • David B. Kaysen / President, CEO
  • Tammy Groene / VP, Ops.
    • Since April , Ms. Groene has provided administrative support and operational management to the Sun BioPharma, Inc. team. Prior to joining Sun BioPharma, Inc., Ms. Groene worked for MGI Pharma, Inc. as the Executive Assistant to the Chief Medical Officer then transitioned into the Marketing Department. Ms. Groene earned her Bachelor of Science degree from St. Cloud State University in St. Cloud, Minnesota.
  • Scott Kellen / Vice President, CFO
    • Prior to joining Sun BioPharma, Inc., Scott was the Chief Financial Officer of Kips Bay Medical, Inc. from through originally joining to help lead them through their initial public offering and multiple followon offerings. In March , Scott also became the Chief Operating Officer. From to , Scott served as Director of Finance for Transoma Medical, Inc., during which time Transoma prepared for its proposed initial public offering, which was withdrawn in February due to deteriorated market conditions. From to , Scott served as the Corporate Controller for ev Inc. during that company s initial public offering and during additional followon offerings. From to , Scott served as Senior Audit Manager of Deloitte amp Touche, LLP now Deloitte LLP , providing auditing and consulting services to midsize public companies adjusting to the requirements of the SarbanesOxley Act of . Altogether, Scott has spent more than years in the medical device industry, serving early stage and growth companies that produced Class II and III devices. Scott has a Bachelor of Science degree in Business Administration from the University of South Dakota and is a Certified Public Accountant inactive .
  • Suzanne Gagnon / CMO
    • has served as our Chief Medical Officer and as a director of our Company since the effective time of the Merger. Ms. Gagnon had previously served as a director of SBP Research since June and as its Chief Medical Officer since January . Previously, Ms. Gagnon served as the Lead Clinical Consultant to the Company. Prior to working for the Company, Ms. Gagnon was the President of Gagnon Consulting LLC from July through December consulting on medical, safety and regulatory matters. From December through July , Ms. Gagnon had acted as the Chief Medical Officer for three companies, ICON Clinical Research, Nupathe, Inc. and Idis, Inc.
  • Thomas X. Neenan / CSO
    • has served as our Chief Scientific Officer and as a director of our Company since the effective time of the Merger. Dr. Neenan is an entrepreneur and scientist with extensive chemistry and business development executive experience with AT amp T Bell Labs, Geltex, Genzyme, Trine Pharma, Warwick Effect Polymers, Gelesis and Proxy Biomedical. He most recently served as Founder and Chief Technology Officer of Sideris Pharmaceuticals Inc, raising M in equity financing in . Dr. Neenan holds a B.Sc Hons in Chemistry and Math from the University College of Dublin in Ireland, a Ph.D in Synthetic Chemistry from Penn State University, and postdoctoral studies in chemistry at Harvard University. Dr. Neenan also brings a wealth of knowledge to the Company on drug manufacture and was instrumental in improving the synthetic process for SBP . He is the author of approximately publications in the fields of chemistry and materials sciences and holds approximately US and international patents.
  • Michael T. Cullen / Executive Chairman
  • Suzanne Gagnon /
    • has served as our Chief Medical Officer and as a director of our Company since the effective time of the Merger. Ms. Gagnon had previously served as a director of SBP Research since June and as its Chief Medical Officer since January . Previously, Ms. Gagnon served as the Lead Clinical Consultant to the Company. Prior to working for the Company, Ms. Gagnon was the President of Gagnon Consulting LLC from July through December consulting on medical, safety and regulatory matters. From December through July , Ms. Gagnon had acted as the Chief Medical Officer for three companies, ICON Clinical Research, Nupathe, Inc. and Idis, Inc.
  • Dr. Dalvir S. Gill / Independent Director, Nominating Committee Member
    • Dalvir S. Gill, Ph.D. has served as a director of our Company since March . Mr. Gill has served as the Chief Executive Officer and a director of TransCelerate BioPharma, Inc., a nonprofit organization focused on improving the health of people around the world by simplifying and enhancing the research and development of innovative new therapies since January . Previously, he was the President of Phase IIIV Drug Development at PharmaNeti , an international contract research organization, from July to December . Dr. Gill earned his B.Sc. in Applied Biology from the University of Hertfordshire and his Ph.D. in Pathobiology from the Royal Free Hospital School of Medicine, University of London. He also holds a diploma in the health economics of pharmaceuticals from the executive program of the Stockholm School of Economics. Dr. Gill has more than years of drug development experience. We believe that Dr. Gill brings strategic insight and leadership and a wealth of experience in the pharmaceutical industry to the Board of Directors, as well as knowledge of the regulatory and clinical requirements associated with the development of new drug compounds.
  • J. Robert Paulson, Jr. / Independent Director, Compensation Committee Member, Nominating Committee Member
    • J. Robert Paulson, Jr., M.B.A. has served as a director of our Company since September . Mr. Paulson has served as President, CEO, and a director of NxThera, Inc., a venturefunded medical device company developing a novel convective water vapor energy system to treat a variety of endourological conditions, including benign prostatic hyperplasia BPH and prostate cancer since . Previously, he was President, CEO and a director of Restore Medical Inc. from until its acquisition by Medtronic in July . He was CFO and VP of Global Marketing for Endocardial Solutions, which was acquired by St. Jude Medical in . Before that, he was the Sr. VP/General Manager of Advanced Bionics, and held several executive positions with Medtronic, including VP/General Manager of the Surgical Navigation Technologies business, VP Corporate Strategy, and Director of Corporate Development. Mr. Paulson has held senior positions in marketing, corporate development, legal and finance at General Mills, and practiced corporate, M amp A and securities law with the Minneapolis law firm of Lindquist amp Vennum. He has served as a director of Veran Medical since , and is a former director of Ablation Frontiers, Vascular Solutions and Medical CV. We believe that Mr. Paulson brings strategic insight and leadership and a wealth of experience in healthcare to the Board of Directors, as well as knowledge of capital markets and early stage companies.
  • David B. Kaysen /
  • Jeffrey Mathiesen / Independent Director, Audit Committee Member, Nominating Committee Member
  • Paul W. Schaffer / Independent Director
    • has served as a director since the effective time of the Merger. Mr. Schaffer had previously served as a director of SBP Research since January . Mr. Schaffer graduated from Minnesota Pharmacy School in . He owned and operated a compounding pharmacy, Bloomington Drug, for years. Mr. Schaffer is an experienced biotech investor.
  • D. Robert Schemel / Independent Director, Audit Committee Member, Compensation Committee Member
    • has served as a director since the effective time of the Merger. Mr. Schemel had previously served as a director of SBP Research since March . Mr. Schemel has over years experience in the agriculture industry. From , Mr. Schemel owned and operated a farming operation in Kandiyohi County, Minnesota, building a acre operation producing corn, soybeans and sugar beets. Mr. Schemel has extensive experience in serving on boards of directors. From he served as a board member for ValAdCo and then from he served as the Chairman of the Board for Phenix Biocomposites. He is currently a member of the Southern Minnesota Beet Sugar Coop which oversees the operation of the largest US sugar processing facility and a molasses desugarization facility in Renville, Minnesota, which has a total economic benefit currently exceeding million annually.

Current Share Structure

  • Market Cap: $31,117,381 - 03/09/2018
  • Authorized: 100,000,000 - 03/01/2018
  • Issue and Outstanding: 3,841,652 - 03/01/2018

 


Recent Filings from (OTC: SNBP)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 16 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 14 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 14 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 16 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 16 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 21 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 21 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 20 2018
Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(6) under the Act
Filing Type: DFiling Source: edgar
Filing Date: March, 06 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 05 2018

 

 


Daily Technical Chart for (OTC: SNBP)

Daily Technical Chart for (OTC: SNBP)


Stay tuned for daily updates and more on (OTC: SNBP)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: SNBP)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in SNBP is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of SNBP and does not buy, sell, or trade any shares of SNBP. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/